Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Assets: 2016-2024

Historic Assets for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $577.7 million.

  • Tg Therapeutics' Assets rose 74.91% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 74.91%. This contributed to the annual value of $577.7 million for FY2024, which is 75.28% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Assets is $577.7 million, which was up 75.28% from $329.6 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Assets ranged from a high of $625.6 million in FY2020 and a low of $193.6 million during FY2022.
  • For the 3-year period, Tg Therapeutics' Assets averaged around $366.9 million, with its median value being $329.6 million (2023).
  • Its Assets has fluctuated over the past 5 years, first surged by 283.80% in 2020, then tumbled by 49.01% in 2022.
  • Tg Therapeutics' Assets (Yearly) stood at $625.6 million in 2020, then plummeted by 39.32% to $379.6 million in 2021, then plummeted by 49.01% to $193.6 million in 2022, then skyrocketed by 70.27% to $329.6 million in 2023, then soared by 75.28% to $577.7 million in 2024.